Navigation Links
ProNAi Announces Preclinical Success for PNT2258 Therapeutic -,Curative Events in Xenograft Mice for Difficult-to-Treat,Non-Hodgkin's Lymphoma

and treat non-transcribed regions of genomes responsible for complex genetic diseases, such as cancer.

By acting at the DNA level, where only one or two copies of the gene exist per cell, treatment can be targeted more efficiently by DNAi(R) drugs. With fewer targets, the activity of a DNAi(R) drug is expected to last longer at lower doses, and reduce some of the toxicity issues prevalent with other marketed therapies. Additionally, DNA-related therapies are potentially more cost effective to produce.

About ProNAi Therapeutics, Inc.

ProNAi Therapeutics, Inc. is a biopharmaceutical drug development company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi(R)), which employs single strands of DNA to target and treat non-transcribed regions of genomes responsible for complex genetic diseases. ProNAi is currently developing multiple DNAi(R)-based drug candidates with the potential to treat multiple cancers, including non-Hodgkin's lymphoma, prostate, breast, and colon cancers. The company's lead drug candidate, PNT2258, which has demonstrated in vivo efficacy in a variety of human tumor xenograft models, is currently in preclinical development. ProNAi is also exploring the potential of DNAi(R)-based therapies for indications such as diabetes, Alzheimer's and inflammatory disease.

ProNAi is based in Kalamazoo, Michigan. For more information, please visit: www.pronai.com.

Contact

Aviator PR
Mario Fante, 617-763-9887
mario@aviator-pr.com


'"/>




Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/14/2014)... 2014  Invivotek L.L.C., a member of the ... that its animal research facility was awarded full ... Accreditation of Laboratory Animal Care International (AAALAC). AAALAC ... worldwide through voluntary accreditation and assessment programs. AAALAC ... use in 38 countries. Invivotek was ...
(Date:7/14/2014)... 14, 2014 Valeant Pharmaceuticals International, Inc. ... today announced it has filed a premerger notification ... (HSR) with the U.S. Federal Trade Commission (FTC) ... (NYSE: AGN). About Valeant Pharmaceuticals ... Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical ...
(Date:7/14/2014)... , July 14, 2014  Mallinckrodt plc (NYSE: ... QCOR ) today announced that the registration statement on Form ... by Mallinckrodt plc on May 16, 2014 and amended on ... Mallinckrodt and Questcor that also constitutes a prospectus of Mallinckrodt, ... on Form S-4 is available on the SEC,s EDGAR system, ...
Breaking Medicine Technology:Invivotek Awarded Full AAALAC Accreditation for Excellence in Laboratory Animal Care and Use 2Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 2Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 3Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 4Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 5Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 2Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 3Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 4Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 5Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 6Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 7
... WASHINGTON, Sept. 19 The Richard B. and ... Birch McCormick,Genomics Center at The George Washington ... the issues and implications around the growing ... This symposium is,intended to provide a valuable ...
... Mich., Sept. 19 A new topical lotion ... eliminate serious skin,infections, but without being systemically absorbed, ... in patients with onychomycosis, or,toenail fungus, a new ... 1 clinical trial are important to the fields ...
Cached Medicine Technology:Personalized Medicine - The Genomic Revolution in Cardiac Care 2Personalized Medicine - The Genomic Revolution in Cardiac Care 3New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects 2New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects 3
(Date:7/14/2014)... (PRWEB) July 14, 2014 The governments ... investment in the Global Mobile Health Solutions market. For ... the Health IT for Economic and Clinical Health Act ... 2009. , Analysts forecast the Global Mobile Health ... 34.88 percent over the period 2013-2018. According to the ...
(Date:7/14/2014)... SingaporeA*STAR,s Bioprocessing Technology Institute (BTI) has entered into ... pharmaceutical company, Roche, to identify novel drug candidates ... partnership brings together BTI,s capabilities in novel antibody ... (mAbs) therapeutics, opening up the possibility of ... death worldwide. , The collaboration makes use ...
(Date:7/14/2014)... The Encino cosmetic dentist ... Lumineers and porcelain veneers. These restorations are an ... preparation and greater loss of healthy tooth tissue. They ... visible flaws on the tooth. Encino dentist Dr. Mastour ... to ensure they offer the most appropriate treatment recommendations ...
(Date:7/14/2014)... Stress can slow a woman,s metabolism and lead to weight ... average age 53, who were asked about their stress levels ... 930 calories and 60 grams of fat. The Ohio State ... burn off those calories and fat. On average, women ... 24 hours burned 104 fewer calories in the seven hours ...
(Date:7/14/2014)... July 14, 2014 KeyPoint Credit Union ... 6th Annual 5K run and one-mile family fun walk. ... the park attractions, and finishes inside Levi’s® Stadium. , ... over $150,000 for the Mission City Community Fund. All ... County. , Seasoned athletes, part-time pavement-pounders and walkers ...
Breaking Medicine News(10 mins):Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 2Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 3Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 4Health News:A*STAR partners Roche to develop new cancer therapeutics 2Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2Health News:Stress May Leave You Heading to the Cookie Jar 2
... a Northwestern University research team to discover a new class ... food and medical technologies. And the compounds are edible. ... (MOFs) that are simple to make. Most other MOFs are ... pop into your mouth and eat, and the researchers have. ...
... Stem cells might be thought of as trunks in ... they can turn into a dazzling variety other cellskidney, brain, ... has the capacity to turn into virtually any cell type ... development of cell therapies, the conquering of age-old diseases or ...
... 2 September, 2010 - Elsevier announced today the publication ... and Andropause Society (EMAS) in the journal Maturitas ... the post-reproductive health of women. The statements cover ... obesity, epilepsy, endometriosis and premature ovarian failure. Each ...
... September cover story of the nation,s leading cancer journal, ... Institute, University of Minnesota, that links capsaicin, a component ... mechanisms of the cancer-promoting effects of capsaicin are not ... a definite connection to formation of skin cancer through ...
... Nurses have a responsibility to respect and support patients who ... law and follow professional guidance at all times, according to ... Journal of Clinical Nursing . Dr Anita ... papers, together with professional and Government guidance documents, official reports ...
... Insomnia and other sleep disorders are very common, yet ... health care professionals. Now the British Association for Psychopharmacology ... of Psychopharmacology , published by SAGE, to guide psychiatrists ... BAP members, representative clinicians with a strong interest in ...
Cached Medicine News:Health News:Edible nanostructures 2Health News:Edible nanostructures 3Health News:Study finds that cancer-causing gene crucial in stem cell development 2Health News:Study finds that cancer-causing gene crucial in stem cell development 3Health News:EMAS publishes position statements about the post-reproductive health of women 2Health News:Medicinal cannabis review highlights dilemmas facing health care professionals 2Health News:Medicinal cannabis review highlights dilemmas facing health care professionals 3Health News:New guidelines to ease sleepless nights 2Health News:New guidelines to ease sleepless nights 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: